← Back
Life

Briefing: Fresh turmoil at the FDA with Prasad’s exit

Strategic angle: Prasad out again, generic Ozempic on its way, and more health news from Morning Rounds

Editorial Staff1 min

Summary

  • Summary pending editorial review.

Key Facts

  • Key facts pending editorial review.

Sources